NASDAQ: IMPLImpel Pharmaceuticals Inc Stock
$1.20+0.04 (+3.45%)
Updated May 26, 2023
IMPL Price
$1.20
Fair Value Price
N/A
Market Cap
$28.45M
52 Week Low
$0.93
52 Week High
$10.75
P/E
-0.26x
P/B
-0.39x
P/S
2.18x
PEG
N/A
Dividend Yield
N/A
Revenue
$15.27M
Earnings
-$109.41M
Gross Margin
49.2%
Operating Margin
-635.89%
Profit Margin
-716.7%
Debt to Equity
-1.89
Operating Cash Flow
-$94M
Beta
0.96
Next Earnings
Jun 5, 2023
Ex-Dividend
N/A
Next Dividend
N/A
IMPL Overview
Impel NeuroPharma Incorporated is developing therapies for patients suffering from central nervous system diseases. The company's pipeline includes TRUDHESA, an upper nasal formulation of dihydroergotamine for the treatment of migraines, INP105, an upper nasal formulation of olanzapine for the treatment of agitation and aggression in autism spectrum disorder, and INP107, an upper nasal formulation of Carbidopa/Levodopa. Impel NeuroPharma was incorporated in 2008 and is headquartered in Seattle, WA.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how IMPL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
IMPL is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
IMPL is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
IMPL's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more IMPL due diligence checks available for Premium users.
Be the first to know about important IMPL news, forecast changes, insider trades & much more!
IMPL News
Valuation
IMPL fair value
Fair Value of IMPL stock based on Discounted Cash Flow (DCF)
Price
$1.20
Fair Value
$4.36
Undervalued by
72.46%
IMPL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
IMPL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.26x
Industry
11.86x
Market
54.23x
IMPL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.39x
Industry
5.18x
IMPL's financial health
Profit margin
Revenue
$4.4M
Net Income
-$30.1M
Profit Margin
-687.7%
IMPL's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
IMPL's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$64.7M
Liabilities
$137.6M
Debt to equity
-1.89
IMPL's short-term assets ($51.88M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IMPL's long-term liabilities ($115.35M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IMPL's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
IMPL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$24.1M
Investing
-$1.0M
Financing
$0.0
IMPL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
IMPL vs Biotech Stocks
Impel Pharmaceuticals Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.